Literature DB >> 19386856

Spectrum of zygomycete species identified in clinically significant specimens in the United States.

E Alvarez1, D A Sutton, J Cano, A W Fothergill, A Stchigel, M G Rinaldi, J Guarro.   

Abstract

Several members of the order Mucorales (subphylum Mucoromycotina) are important agents of severe human infections. The identification of these fungi by using standard mycologic methods is often difficult and time consuming. Frequently, the etiological agent in clinical cases is reported either as a Mucor sp., which is not the most frequent genus of zygomycetes, or only as a member of the Mucorales. For this reason, the actual spectrum of species of zygomycetes and their incidences in the clinical setting is not well known. The goals of this study were to compare the results of the molecular identification of an important set of clinical isolates, received in a mycological reference center from different regions of the United States, with those obtained by using the traditional morphological methods and to determine the spectrum of species involved. We tested 190 isolates morphologically identified as zygomycetes by using sequencing of the internal transcribed spacer (ITS) region of the ribosomal DNA. Molecular identification revealed that Rhizopus oryzae represented approximately half (44.7%) of these isolates. The remainder was identified as Rhizopus microsporus (22.1%), Mucor circinelloides (9.5%), Mycocladus corymbifer (formerly Absidia corymbifera) (5.3%), Rhizomucor pusillus (3.7%), Cunninghamella bertholletiae (3.2%), Mucor indicus (2.6%), Cunninghamella echinulata (1%), and Apophysomyces elegans (0.5%). The most common anatomic sites for clinically significant zygomycetes, as determined by isolates sent to the Fungus Testing Laboratory for identification and/or susceptibility testing and included in this study, were the sinuses, lungs, and various cutaneous locations, at 25.8%, 26.8%, and 28%, respectively. These sites represented approximately 80% of the isolates evaluated. A high level of correlation (92.6%) between morphological and molecular identifications was found.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19386856      PMCID: PMC2691065          DOI: 10.1128/JCM.00036-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

1.  Basic local alignment search tool.

Authors:  S F Altschul; W Gish; W Miller; E W Myers; D J Lipman
Journal:  J Mol Biol       Date:  1990-10-05       Impact factor: 5.469

Review 2.  Sequence-based identification of Aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here?

Authors:  S A Balajee; A M Borman; M E Brandt; J Cano; M Cuenca-Estrella; E Dannaoui; J Guarro; G Haase; C C Kibbler; W Meyer; K O'Donnell; C A Petti; J L Rodriguez-Tudela; D Sutton; A Velegraki; B L Wickes
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

3.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.

Authors:  J D Thompson; T J Gibson; F Plewniak; F Jeanmougin; D G Higgins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

4.  Zygomycosis in the 1990s in a tertiary-care cancer center.

Authors:  D P Kontoyiannis; V C Wessel; G P Bodey; K V Rolston
Journal:  Clin Infect Dis       Date:  2000-06-13       Impact factor: 9.079

5.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Authors:  Dimitrios P Kontoyiannis; Michail S Lionakis; Russell E Lewis; Georgios Chamilos; Mimi Healy; Cheryl Perego; Amar Safdar; Hagop Kantarjian; Richard Champlin; Thomas J Walsh; Issam I Raad
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

6.  Phylogeny and PCR identification of clinically important Zygomycetes based on nuclear ribosomal-DNA sequence data.

Authors:  K Voigt; E Cigelnik; K O'donnell
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

Review 7.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

Review 8.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

9.  In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method.

Authors:  Jagpal Singh; Dagmar Rimek; Reinhard Kappe
Journal:  Mycoses       Date:  2005-07       Impact factor: 4.377

Review 10.  Zygomycosis (mucormycosis): emerging clinical importance and new treatments.

Authors:  Richard N Greenberg; Lauren J Scott; Heather H Vaughn; Julie A Ribes
Journal:  Curr Opin Infect Dis       Date:  2004-12       Impact factor: 4.915

View more
  57 in total

1.  Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus Saksenaea.

Authors:  E Alvarez; D Garcia-Hermoso; D A Sutton; J F Cano; A M Stchigel; D Hoinard; A W Fothergill; M G Rinaldi; F Dromer; J Guarro
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

2.  In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.

Authors:  Sharon C-A Chen; Chayanika Biswas; Robyn Bartley; Fred Widmer; Namfon Pantarat; Daniel Obando; Julianne T Djordjevic; David H Ellis; Katrina A Jolliffe; Tania C Sorrell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

3.  Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.

Authors:  Roxana G Vitale; G Sybren de Hoog; Patrick Schwarz; Eric Dannaoui; Shuwen Deng; Marie Machouart; Kerstin Voigt; Wendy W J van de Sande; Somayeh Dolatabadi; Jacques F Meis; Grit Walther
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

4.  Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.

Authors:  Ana Alastruey-Izquierdo; Isabel Cuesta; Grit Walther; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

Review 5.  Mucormycosis, pseudallescheriasis, and other uncommon mold infections.

Authors:  Clifford Quan; Brad Spellberg
Journal:  Proc Am Thorac Soc       Date:  2010-05

6.  Improving molecular detection of fungal DNA in formalin-fixed paraffin-embedded tissues: comparison of five tissue DNA extraction methods using panfungal PCR.

Authors:  C Muñoz-Cadavid; S Rudd; S R Zaki; M Patel; S A Moser; M E Brandt; B L Gómez
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

7.  Clinical experience in invasive fungal infections.

Authors:  Patrícia Pacheco; Ana Sofia Ventura; Teresa Branco; Lucília Gonçalves; Célia Carvalho
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

8.  Internal transcribed spacer region sequence heterogeneity in Rhizopus microsporus: implications for molecular diagnosis in clinical microbiology laboratories.

Authors:  Patrick C Y Woo; Shui-Yee Leung; Kelvin K W To; Jasper F W Chan; Antonio H Y Ngan; Vincent C C Cheng; Susanna K P Lau; Kwok-Yung Yuen
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

9.  Identification of fungal pathogens in a patient with acute myelogenic leukemia using a pathogen detection array technology.

Authors:  Sagarika Banerjee; Kristen N Peck; Michael D Feldman; Mindy G Schuster; James C Alwine; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742

10.  Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.

Authors:  M Mar Rodríguez; F Javier Pastor; Enrique Calvo; Valentina Salas; Deanna A Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.